Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa monotherapy in HMGA2-expressing triple negative breast cancer (Phase II)
2019-004833-18Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in triple-negative breast cancer (TNBC), sponsored by Merck KGaA. Primary endpoint: Confirmed objective response rate (ORR). Started Jul 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2019-004833-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004833-18.